Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Glofitamab”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07240194
What this trial is testing

The Efficacy and Safety of Glofitamab in Combination With PD-1 Antibody and Lenalidomide in Patients With Relapsed/Refractory Large B-cell Lymphoma (LBCL) With TP53 Aberrations: A Prospective, Multicenter, Phase II Clinical Study

Who this might be right for
Large B-cell LymphomaTP53
The First Affiliated Hospital with Nanjing Medical University 24
Testing effectiveness (Phase 2)Looking for participantsNCT07453095
What this trial is testing

Study With Glofitamab in Patients With MCL and Inadequate Response or Relapse Following CAR T-cell Therapy

Who this might be right for
Mantle Cell Lymphoma
Fondazione Italiana Linfomi - ETS 41
Early research (Phase 1)Study completedNCT04313608
What this trial is testing

A Study Evaluating the Safety and Efficacy of Glofitamab or Mosunetuzumab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and High-Grade Large B-Cell Lymphoma

Who this might be right for
B-cell Lymphoma
Hoffmann-La Roche 23
Testing effectiveness (Phase 2)Looking for participantsNCT07003295
What this trial is testing

Testing the Anti-cancer Drug, Glofitamab, in Patients With Mantle Cell Lymphoma (A Type of Blood Cancer) Whose Disease Returned After CAR-T Cell Therapy

Who this might be right for
Recurrent Mantle Cell LymphomaRefractory Mantle Cell Lymphoma
National Cancer Institute (NCI) 20
Early research (Phase 1)Study completedNCT03467373
What this trial is testing

Glofitamab in Combination With Rituximab or Obinutuzumab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP), or Polatuzumab Vedotin Plus Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone (CHP) in Participants With Non-Hodgkin Lymphomas or With DLBCL

Who this might be right for
B-Cell LymphomaNon-Hodgkin Lymphoma
Hoffmann-La Roche 111
Testing effectiveness (Phase 2)Looking for participantsNCT06050694
What this trial is testing

Feasibility Trial of Glofitamab in a Response Adapted Approach Incorporating Interim FDG PET and ctDNA to Optimize Primary Therapy of DLBCL (GRAIL)

Who this might be right for
Diffuse Large B Cell Lymphoma (DLBCL)
University Health Network, Toronto 40
Early research (Phase 1)Active Not RecruitingNCT04231877
What this trial is testing

Polatuzumab Vedotin and Combination Chemotherapy With or Without Glofitamab for the Treatment of Untreated Aggressive Large B-cell Lymphoma

Who this might be right for
Aggressive Non-Hodgkin LymphomaALK-Positive Large B-Cell LymphomaDiffuse Large B-Cell Lymphoma, Not Otherwise Specified+6 more
University of Washington 56
Early research (Phase 1)Study completedNCT04657302
What this trial is testing

Evaluate Glofitamab as Single Agent Administered After Pretreatment With Obinutuzumab in Chinese Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
Hoffmann-La Roche 30
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07502872
What this trial is testing

TPG: Tafasitamab, Polatuzumab Vedotin, and Glofitamab as First-line Therapy for Diffuse Large B-cell Lymphoma and High-grade B-cell Lymphoma

Who this might be right for
Diffuse Large B Cell LymphomaHigh-grade B-cell LymphomaLymphoma+1 more
Brown University 30
Testing effectiveness (Phase 2)Looking for participantsNCT06682130
What this trial is testing

Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL

Who this might be right for
Diffuse Large B-cell Lymphoma(DLBCL)
The First Affiliated Hospital of Soochow University 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT05335018
What this trial is testing

GPL in Patients with Relapsed/refractory Diffuse Large B Cell Lymphoma

Who this might be right for
Relapsed/refractory Diffuse Large B Cell Lymphoma
Seoul National University Hospital 76
Large-scale testing (Phase 3)Looking for participantsNCT06084936
What this trial is testing

Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

Who this might be right for
Lymphoma
Hoffmann-La Roche 182
Early research (Phase 1)Looking for participantsNCT06624085
What this trial is testing

A Study Evaluating the Safety and Efficacy of Glofitamab + Gemcitabine + Oxaliplatin in U.S. Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Who this might be right for
Lymphoma
Hoffmann-La Roche 50
Not applicableLooking for participantsNCT07200375
What this trial is testing

An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

Who this might be right for
Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche 300
Testing effectiveness (Phase 2)Looking for participantsNCT06071871
What this trial is testing

A Trial of Polatuzumab Vedotin, Obinutuzumab and Glofitamab As a Peri-CAR-T Cell Treatment Strategy in Large B-cell Lymphoma

Who this might be right for
Large B-cell Lymphoma
University College, London 99
Not applicableNot Yet RecruitingNCT07695896
What this trial is testing

Real-World Study of Bispecific Antibody in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

Who this might be right for
Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Yanyan Liu 200
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07643805
What this trial is testing

Single-Arm Clinical Study of EZH2i in Combination With Glofitamab + GemOx in Patients With Relapsed/ Refractory DLBCL

Who this might be right for
DLBCL
The First Affiliated Hospital with Nanjing Medical University 46
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07613788
What this trial is testing

Rimegepant Plus Glofitamab and CD19 CAR-T Therapy in R/R LBCL

Who this might be right for
Relapsed/Refractory Large B-cell Lymphoma (LBCL)
Ruijin Hospital 100
Testing effectiveness (Phase 2)Ended earlyNCT05896163
What this trial is testing

Learn About the Effects of Two Study Medicines (Maplirpacept [PF-07901801] And Glofitamab) When Given Together In People With Relapsed Or Refractory Diffuse Large B Cell Lymphoma.

Who this might be right for
Diffuse Large B-Cell Lymphoma
Pfizer 40
Testing effectiveness (Phase 2)Active Not RecruitingNCT03533283
What this trial is testing

An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Who this might be right for
Non-Hodgkins Lymphoma
Hoffmann-La Roche 211
Next Page